$668.5 M

APLT Mkt cap, 26-Mar-2020
Applied Therapeutics Net income (FY, 2019)-45.5 M
Applied Therapeutics EBIT (FY, 2019)-45.6 M
Applied Therapeutics Cash, 31-Dec-201918.9 M
Applied Therapeutics EV651.7 M

Applied Therapeutics Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019

R&D expense

3.7m11.5m32.4m

General and administrative expense

582.0k2.0m13.2m

Operating expense total

4.3m13.5m45.6m

EBIT

(4.3m)(13.5m)(45.6m)

Interest expense

93.0k

Income tax expense

Net Income

(4.3m)(16.5m)(45.5m)

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019

R&D expense

6.9m4.3m7.5m

General and administrative expense

1.9m4.2m3.3m

Operating expense total

8.7m8.4m10.7m

EBIT

(8.7m)(8.4m)(10.7m)

Interest expense

1.0k34.0k

Net Income

(8.7m)(8.4m)(10.7m)

Applied Therapeutics Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

3.3m18.7m18.9m

Prepaid Expenses

9.0k1.5m7.3m

Current Assets

3.3m20.2m46.2m

Total Assets

3.3m20.2m48.4m

Accounts Payable

713.0k3.0m8.8m

Short-term debt

356.0k

Current Liabilities

993.0k4.4m14.1m

Long-term debt

1.7m

Non-Current Liabilities

1.7m

Total Debt

2.0m

Total Liabilities

993.0k4.4m15.8m

Common Stock

1.0k

Preferred Stock

6.3m35.4m

Additional Paid-in Capital

775.0k1.7m99.4m

Retained Earnings

(4.7m)(21.3m)(66.8m)

Total Equity

2.3m15.8m32.6m

Financial Leverage

1.4 x1.3 x1.5 x

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019

Cash

14.7m41.1m13.1m

Prepaid Expenses

2.2m5.7m4.1m

Current Assets

16.9m46.8m37.0m

Total Assets

16.9m46.8m37.3m

Accounts Payable

2.6m4.0m1.7m

Current Liabilities

6.3m6.8m6.5m

Total Liabilities

6.3m6.8m6.5m

Common Stock

5.5m1.0k1.0k

Additional Paid-in Capital

2.1m78.4m79.9m

Retained Earnings

(30.0m)(38.4m)(49.1m)

Total Equity

(27.9m)40.0m30.7m

Financial Leverage

-0.6 x1.2 x1.2 x

Applied Therapeutics Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

(4.3m)(16.5m)(45.5m)

Accounts Payable

5.8m

Cash From Operating Activities

(3.2m)(11.2m)(36.3m)

Cash From Investing Activities

(20.0m)

Cash From Financing Activities

6.5m26.7m56.4m

Net Change in Cash

3.3m18.7m102.0k

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019

Net Income

(8.7m)(17.2m)(27.9m)

Accounts Payable

(366.0k)462.0k(1.3m)

Cash From Operating Activities

(7.0m)(16.1m)(23.9m)

Cash From Investing Activities

(19.9m)

Cash From Financing Activities

2.9m38.4m38.1m

Net Change in Cash

(4.1m)22.3m(5.7m)

Applied Therapeutics Ratios

USDY, 2019

EV/EBIT

-14.3 x

EV/CFO

-18 x

Financial Leverage

1.5 x

Applied Therapeutics Operating Metrics

Q1, 2019

Phase II Patients Enrolled

120